Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 429Breast Neoplasms 298Neoplasms 296Colorectal Neoplasms 242Neoplasm Metastasis 197Ovarian Neoplasms 171Lung Neoplasms 150Recurrence 147Prostatic Neoplasms 146Pancreatic Neoplasms 142Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 115Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 62

Interventions

Tirapazamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × HCC × Clear all
NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting
300 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡